TRIB VS CFMS Stock Comparison

PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatility
PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatility

Performance

TRIB
10/100

TRIB returned -60.18% in the last 12 months. Based on SPY's performance of -21.29%, its performance is below average giving it a score of 10 of 100.

CFMS
10/100

CFMS returned -70.49% in the last 12 months. Based on SPY's performance of -7.21%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

TRIB
83/100

3 analysts offer 12-month price targets for TRIB. Together, they have an average target of 0, the most optimistic target put TRIB at 0 within 12-months and the most pessimistic has TRIB at 0.

CFMS
61/100

7 analysts offer 12-month price targets for CFMS. Together, they have an average target of 0, the most optimistic target put CFMS at 0 within 12-months and the most pessimistic has CFMS at 0. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.

Sentiment

TRIB
67/100

TRIB had a bullish sentiment score of 67.18% across Twitter and StockTwits over the last 12 months. It had an average of 5.22 posts, 3.44 comments, and 2.83 likes per day.

CFMS

"Sentiment" not found for CFMS

Technicals

TRIB
11/100

TRIB receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

CFMS
71/100

CFMS receives a 71 of 100 based on 14 indicators. 10 are bullish, 4 are bearish.

Earnings

TRIB
10/100

TRIB has missed earnings 10 times in the last 20 quarters.

CFMS
10/100

CFMS has missed earnings 8 times in the last 20 quarters.

Profit

TRIB
48/100

Out of the last 20 quarters, TRIB has had 14 profitable quarters and has increased their profits year over year on 4 of them.

CFMS
10/100

Out of the last 20 quarters, CFMS has had 1 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

TRIB
50/100

TRIB has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

CFMS
43/100

CFMS has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Trinity Biotech plc Summary

Nasdaq / TRIB
Healthcare
Medical - Diagnostics & Research
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Conformis, Inc. Common Stock Summary

Nasdaq / CFMS
Healthcare
Medical Devices
Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, a custom-made partial knee replacement option for either unicompartmental or bicompartmental osteoarthritis of the knee; iTotal CR, a cruciate retaining total knee replacement product; iTotal PS, a posterior stabilized knee replacement product, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.